Regulated information
Waregem (Belgium)/Rotterdam (The Netherlands)1, 4 July 2016
Fagron NV (the “Company”) announces that its extraordinary general meeting of shareholders, held on 1 July 2016, has adopted all proposed resolutions. The meeting adopted, amongst other, the Warrant Plan 2016 and decided to reduce the Company’s share capital with € 54,182,316.27 to € 405,926,861.28, by incorporating the same amount of the losses transferred (as first allocated to the Company’s (un)available reserves), without cancellation of shares.
In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.
For more information:
Constantijn van Rietschoten
Chief Marketing Officer
Tel. +31 6 53 69 15 85
constantijn.van.rietschoten@fagron.com
Fagron profile
Fagron is the leading global pharmaceutical compounding company, bringing customized pharmaceutical care to hospitals, pharmacies, clinics and patients in 32 countries worldwide.
The Belgian company Fagron NV is located in Waregem and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol ‘FAGR’. The operational activities of Fagron are driven by the Dutch company Fagron BV. The head office of Fagron BV is located in Rotterdam.
1 This press release was sent out by Fagron NV and Fagron BV.
Please open the link below for the press release: